| pubmed-article:7533518 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C0014582 | lld:lifeskim |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C0020823 | lld:lifeskim |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C1705822 | lld:lifeskim |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C0439228 | lld:lifeskim |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C1511572 | lld:lifeskim |
| pubmed-article:7533518 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:7533518 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:7533518 | pubmed:dateCreated | 1995-4-12 | lld:pubmed |
| pubmed-article:7533518 | pubmed:abstractText | Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim). Complete remission occurred in six out of the 20 patients (30%, 95% confidence interval 12-54%) and there were 12 partial responders (60%, 95% confidence interval 37-81%), thus giving an overall response rate of 90% (95% confidence interval 63-97%). Two patients had progressive disease. The median duration of response for those patients with metastatic disease was 7.3 (1.3-20.1+) months. The median survival time for these patients was 15 (5.3-27.9+) months. Of the four patients treated with locally advanced disease three achieved a complete clinical response and one a partial response. Three out of four of these patients subsequently underwent a mastectomy, and in one of these no viable tumour was seen. Our conclusion is that this regimen is excellent palliation for metastatic disease and possibly useful neoadjuvant treatment. | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7533518 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7533518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7533518 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7533518 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:7533518 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:LandE JEJ | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:CalvertA HAH | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:SimmondsDD | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:CantwellB MBM | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:MillwardM JMJ | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:ProctorMM | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:ChapmanFF | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:McCannEE | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:GumbrellLL | lld:pubmed |
| pubmed-article:7533518 | pubmed:author | pubmed-author:MiddletonII | lld:pubmed |
| pubmed-article:7533518 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7533518 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:7533518 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7533518 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7533518 | pubmed:pagination | 610-3 | lld:pubmed |
| pubmed-article:7533518 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:meshHeading | pubmed-meshheading:7533518-... | lld:pubmed |
| pubmed-article:7533518 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7533518 | pubmed:articleTitle | The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. | lld:pubmed |
| pubmed-article:7533518 | pubmed:affiliation | Department of Clinical Oncology, Newcastle General Hospital, Newcastle upon Tyne, UK. | lld:pubmed |
| pubmed-article:7533518 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7533518 | pubmed:publicationType | Clinical Trial | lld:pubmed |
